Gilead Sciences, Inc. GILD announced Saturday, it will present 32
scientific presentations related to its approved medicines and
investigational therapies for the treatment of chronic hepatitis C virus
(HCV) infection at The Liver Meeting 2015 in San Francisco. Data include
results from studies of Harvoni® (ledipasvir/sofosbuvir) and
Sovaldi® (sofosbuvir) that advance the understanding of the
profiles of these drugs in several patient populations. Detailed results
from the four Phase 3 ASTRAL studies evaluating the company's next
potential single tablet regimen – a once-daily combination of
velpatasvir (VEL), an investigational pan-genotypic NS5A inhibitor, with
sofosbuvir (SOF) – also will be presented.
"We continue to advance our understanding of the safety and efficacy of
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in